地西他滨治疗骨髓增生异常综合征转为急性髓系白血病完全缓解1例并文献复习  

Case report with literatures review on Decitabine treatment of myelodysplastic syndromes into acute myeloid leukemia in complete remission

作　　者：杨华[1] 朱海燕[1] 韩晓萍[1] 王全顺[1] 于力[1] 

机构地区：[1]解放军总医院血液科,北京100853

出　　处：《中国医药导报》2012年第36期117-119,共3页China Medical Herald

基　　金：国家自然科学基金(项目批准号:30572108);国家自然科学基金(项目批准号:30670898)

摘　　要：通过介绍地西他滨治疗1例骨髓增生异常综合征(myelodysplastic syndrome,MDS)转为急性髓系白血病(acutemyeloid leukemia,AML)的患者达到完全缓解的治疗过程,了解抗肿瘤新药DNA甲基化转移酶抑制剂地西他滨的疗效及副作用。地西他滨对MDS患者能明显改善生活质量,减轻输血的依赖,甚至能够使向白血病转化的MDS患者达到完全缓解,但有骨髓抑制的副作用。并通过文献复习来全面介绍近几年地西他滨的临床研究情况,为临床应用该药提供帮助。Introduction Decitabine to treatment of patients with MDS into AML patients achieved complete remission dur- ing the treatment, in order to learn about the efficacy and side effects of anti-tumor drugs DNA methylation inhibitor Decitabine. Decitabine for MDS patients can significantly improve the quality of life, reduce transfusion dependence, even able to make the transformation to leukemia patients achieved complete remission with the side effect of bone marrow sup- pression. And a comprehensive review of the literatures is made to Decitabine clinical application in recent years, to pro- vide help for the clinical application of the medicine.

关 键 词：地西他滨 骨髓增生异常综合征 急性髓系白血病 化疗 副作用 

分 类 号：R551.3[医药卫生—血液循环系统疾病]